Special Session

Brain Disorder 2019







6th International Conference on

Brain Disorders and Therapeutics

July 01-02, 2019 | Paris, France

Insights on Brain Dynamic Imaging

Gonzague DE Raulin
Brain Dynamic Imaging, France

Our mission is to achieve this technological feat that produces unparalleled functional and molecular images of the brain. The reliable early neurological diagnosis finally becomes accessible to the greatest number.

With the patient: Deliver a comfort space, Lighten your caring environment, Shorten his exam, Protect it by reducing the dose to inject, Detect precisely his pathology for a better care.

From practitioners: Improve early diagnosis thanks to a more precise, more sensitive and dynamic image, Guide therapeutic choices, Facilitate therapeutic follow-up, Take advantage of an innovative tool for research and therapeutic innovation, Reduce the acquisition time and therefore the examination time

From hospitals: Increase the number of exams, Reduce the cost of maintenance, Decrease capital and cost of ownership, Optimize the performance of the nuclear medicine service.

With health authorities: Taking into account the objectives of the ASN (reduction of the injected dose), Increased chance to better care, Exam quality, Reducing health costs for the community.

Speaker Biography

Gonzague DE Raulin has a 17 years 'experience in Med-Tech Biotech. Industrial designer from KEDGE Business Scholl he has follow up with an MSc in design and strategic Management in the UK. He will be in charge of design and product development at Winncare International then as International Marketing and new product development for long term care at Hill-Rom. He will put in place a coercive vision of corporate Social responsibility at the NYSE taking care of the WHO guide line. He works with various University all along the process such as : Berkeley, Columbia, instead within best practice in mind. He has follow the HEC Executive general Management programme.

e: deraulingonzague@yahoo.fr

Notes:

Scientific Tracks & Sessions
July 01, 2019

Brain Disorder 2019







6th International Conference on

Brain Disorders and Therapeutics

July 01-02, 2019 | Paris, France

Sessions on

Day 1 | July 01, 2019

Brain Disorders | Neuropharmacology and Neuro-therapeutics | Animal Models in Brain Research | Pediatric Neurology | Advances in Neuroimaging

Chair
Theodore A Henderson
Neuro-Laser Foundation | USA

Co-Chair
Gabriele Saretzki
Newcastle University | UK

Session Introduction

Title: Pharmacotherapy with Sertraline improves Brain development and Behavior in a mouse model of CDKL5 Deficiency Disorder

Elisabetta Ciani | University of Bologna | Italy

Title: How to use your Brain to motivate yourself

Max Leone | Licensed NLP Trainer | Italy

Title: Therapeutic potential of targeting microtubule defects in a mouse model of CDKL5 Deficiency Disorder

Kilstrup-Nielsen C | University of Insubria | Italy

Title: Arsha Vidya program for preventing drug abuse among disadvantaged children in urban slums

Rajubhai P Odedra | NMP Medical Research Institute | India

allied academies

6th International Conference on

Brain Disorders and Therapeutics

July 01-02, 2019 | Paris, France

Pharmacotherapy with Sertraline improves Brain development and Behavior in a mouse model of CDKL5 Deficiency Disorder

Elisabetta Ciani, Claudia Fuchs, Laura Gennaccaro, Stefania Trazzi and **Giuseppe Galvani**
University of Bologna, Italy

CDKL5 deficiency disorder (CDD) is a rare neurodevelopmental disease caused by de novo mutations in the X-linked CDKL5 gene. The consequent misexpression of the CDKL5 protein in the nervous system leads to a severe phenotype characterized by intellectual disability, motor impairment, visual deficits and early-onset epilepsy. No therapy is available for this devastating disorder. Recent studies have implicated alterations in serotonin (5-HT) signaling in neurodevelopmental disorders (NDDs), such as autism spectrum disorders, RTT and Down syndrome, suggesting that drugs targeting the 5-HT system might be a valid treatment option for NDDs. Interestingly, we found a deregulation of the 5-HT2A receptor expression, an important player in cognitive processes, in the hippocampus and cortex of an animal model of CDD, the Cdkl5 knockout (KO) mouse, suggesting a Cdkl5-dependent dysregulation of the 5-HT system. Importantly we found that treatment with Sertraline, a selective serotonin reuptake inhibitor, improved brain development and behavior in Cdkl5 KO mice. Our result might represent a fundamental pre-clinical step with a high translational impact for the amelioration of CDKL5-related symptoms.

Speaker Biography

Elisabetta Ciani, PhD, Neurophysiologist. Professor of Physiology at the Medical School of the University of Bologna. Trained in genetic, molecular and cellular biology during her postdoc at the Max Planck Institute, Munich (1995-1999). Dr. Ciani is an expert in dendrite and synapse development in the Central Nervous System. In particular, she studies development of dendritic spines and neuronal maturation in various models of neurodevelopmental disorders including Down syndrome and CDKL5 disorder. Her group has collaborated to develop a first mice model of the CDKL5 disorder. She has developed a protein therapy for CDKL5 disorder (inventor, Patent WO2015128746A3). She has 76 publications, and her publication H-index is 35.

e: elisabetta.ciani@unibo.it

Notes:

allied academies

6th International Conference on

Brain Disorders and Therapeutics

July 01-02, 2019 | Paris, France

How to use your Brain to motivate yourself

Max Leone
Licensed NLP Trainer, Italy

Problem statement: We see a significant number of people who know what they want to create in life, and yet they find it hard to motivated themselves to go through the action steps required to succeed. We also see people who feel drawn towards something they know is not beneficial to them, and yet they keep pursuing it just because they feel "compelled" to do so. The common issue is that their choices and their motivation are out of alignment. The common reaction is to use self-discipline "to get things done," which causes an inner conflict that quickly depletes our energy, making it hard to perform at the level of excellence. Because of that, they start to experience a sense of frustration, guilt, and helplessness that results in a strong decrease in personal productivity.

Discoveries: It has been discovered that lack of motivation is simply caused by the weakness of a desire, rather than being a deficiency of the individual, and that by changing the way we represent our goals, we can stimulate a strong drive to move away or towards something in everyone. Therefore, motivation is something that each and all of us have as, and the way to fill the gap between what we want (provided that it is congruent with our values) and the willingness to act at the best of our ability is to change the inner representation of the object of our desire.

Conclusion & Significance: To do so there are principles that can be applied successfully to everyone indistinctly, and specific ones that are unique to each individual allowing them to tap into greater levels of motivation. By doing so we will go from being a passive witness of the rising and falling of motivation to a conscious creator who is able address it in the pursuit of worthwhile goals.

Speaker Biography

Max Leone is a professional speaker, coach and author who has been involved in the personal growth field for more than ten years. He studied with some of the greatest masters in the field, such as Wayne Dyer, Deepak Chopra, Neale Walsh, Anthony Robbins, Eckhart Tolle. Max studied NLP with the founder Richard Bandler, with whom he became a Certified Trainer of Neuro-Linguistic-Programming. He qualified and studied extensively a variety of disciplines such as Translation Analysis, ACT *(Acceptance and Commitment Therapy)*, The Sylva Method, Hypnosis, DHE *(Designing human Engineering)* and other techniques he uses with individuals and groups. He has been interviewed on radio stations, such as *New York Coaching Common Radio, 103.2, Radio Dublin,* and his work has been featured in magazines and newspapers, among which are Positive Life, The Irish Times, New Thoughts Magazines, to mention some. Max is the author of "Daily Tips for Success & Fulfilment".

e: m.leone@maxleone.com

Notes:

allied academies

6th International Conference on

Brain Disorders and Therapeutics

July 01-02, 2019 | Paris, France

Therapeutic potential of targeting microtubule defects in a mouse model of CDKL5 Deficiency Disorder

Kilstrup-Nielsen C[1], Barbiero I[1], Rusconi L, Tramarin T[1], De Rosa R[1] and **Bianchi M[2]**

[1]University of Insubria, Italy

[2]Trinity College Dublin, Ireland

Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) cause CDKL5-deficiency disorder (CDD), a neurological pathology characterised by severe infantile seizures, intellectual disability, hypotonia, and impairment of motor, language and hand function skills. CDKL5-knockout (KO) mouse models recapitulate most features of the human disorder including impaired learning and memory. The absence of CDKL5 causes defective spine maturation that can at least in part explain the cognitive impairment of both CDKL5 patients and mouse models. The molecular basis for such defect is not clear but may partly depend on altered microtubule (MT) dynamics. Indeed, we recently demonstrated that CDKL5 regulates MT dynamics through CLIP170, a plus end binding protein the mutations of which are responsible for human intellectual disability. Our studies suggest that CLIP170 contributes significantly to the neuronal impairment of CDD and represent an important druggable target for patients with CDKL5 mutations. The neurosteorid pregnenolone (PREG) can directly bind and activate CLIP170. Here we present our data showing that its synthetic derivative pregnenolone-methyl-ether (PME) rescues CLIP170 functioning in CDKL5 deficient cells and normalizes neuroanatomic, molecular, and behavioural defects in a mouse model of CDD.

Speaker Biography

Kilstrup-Nielsen C has been working in the University of Insubria, Department of Biotechnology and Life Sciences Laboratory of Molecular Neurobiology.

e: c.kilstrup-nielsen@uninsubria.it

Notes:

allied academies

6th International Conference on

Brain Disorders and Therapeutics

July 01-02, 2019 | Paris, France

Arsha Vidya program for preventing drug abuse among disadvantaged children in urban slums

Rajubhai P Odedra[1], Buddhatmananda Saraswati [1,2] and **Divya Gaur [1,3]**

[1]NMP Medical Research Institute, India

[2]Arsha Vidya Study Centre, India

[3]United Research International, India

Substance abuse remain critical problems in both developed and developing countries. Under privileged communities where health and economic system is weakest, use of drugs and illicit substances starts during adolescence and young adulthood. This not just affect physical development, mental health and social integration, but also family formation and stability, deviant behavior, sexual behavior and involvement, educational pursuits, livelihood pursuits. Therefore, emphasizes the need for preventive education at this impressionable age. Present study was part of Global Research Initiative of Arshavidya where adolescents with substance abuse were recruited from community centers and primary care.

All participants underwent 18-weeks of Arshavidya intervention program, An unique well-planned teaching program developed to educate Indian cultural values & heritage to young children and adults with yoga, chants, religious and spiritual practices through stories, group activities and plays. After the program impact which were reported in intervention group compared to waitlist control were significant in overall well-being, Percent days abstinent of tobacco, alcohol and drugs and withdrawal symptoms. Community program with integrated approach could be helpful taking young children off to drug and substance abuse. Further long-term results are needed.

Speaker Biography

Rajubhai Popat Odedra has been working on Global Research Initiative of Arsha Vidya to support young children and adolescents through community interventions. He has been part of collaborative multicentric research program and has been invited to international meetings and conferences to share the outcome.

e: nmpmedicalresearch@gmail.com

Notes: